Findings from a Scientific Online Poster presented during the 2023 ARRS Annual Meeting at the Hawaiian Convention Center suggest there is institutional variability in both projection order and image acquisition timing for contrast-enhanced mammography (CEM) protocol

Example of “downgrading” finding to a less conspicuous finding. Earlier-obtained image described as mass and later-obtained image described as non-mass enhancement by same reader for images of same patient 


April 26, 2023 — Findings from a Scientific Online Poster presented during the 2023 ARRS Annual Meeting at the Hawaiian Convention Center suggest there is institutional variability in both projection order and image acquisition timing for contrast-enhanced mammography (CEM) protocol, with a previous systematic review revealing at least 7 different combinations in projection order. 

“Our study demonstrates that earlier-obtained recombined imaging is significantly preferred in cancer lesion characterization, with a few instances demonstrating that biopsy-proven lesions may appear more conspicuously on earlier-obtained imaging (e.g., mass versus non-mass enhancement),” said Dennis Dwan, MD, of Beth Israel Deaconess Medical Center in Boston, MA. Also noting a preference trend for craniocaudal (CC) over mediolateral oblique (MLO) projection, “given better characterization on earlier imaging,” Dr. Dwan added, “CEM protocols should consider prioritizing imaging the side of pathology.” 

In Dwan et al.’s study, two groups of consecutive CEM cases were performed on patients prior to cancer diagnosis: 40 cases, from 2016 to 2018, acquired with CC views performed first; 38 cases, from 2019 to 2020, acquired with MLO views performed first. The side of pathology was initially imaged in either the CC or MLO projection (earlier-obtained imaging), followed by the contralateral side in the same projection. Then, imaging was repeated for the other projection (later-obtained imaging). Five readers evaluated cases for cancer visibility, confidence margin, and cancer conspicuity against background parenchymal enhancement (BPE). Additional analysis compared earlier- and later-obtained images, as well as CC compared to MLO projection. 


In this ARRS Annual Meeting Online Poster, 78 female patients were included (mean age, 58 years). Ultimately, no significant difference was shown in menopausal status, breast density, or BPE between group 1 and 2. Mean acquisition time of the earlier- and later-obtained imaging was 2.5 minutes and 4.75 minutes, respectively. In 35/390 (9%) of instances, an individual reader changed the reported lesion type between earlier and later imaging, with most instances (n = 28/35, 80%) reflecting a situation where a finding was downgraded to a less conspicuous finding on later-obtained imaging. 

Overall, reader preference was for earlier-obtained images when assessing visibility of cancer, confidence in margins, and conspicuity of lesion against BPE (p < 0.001). Among all readers, there was preference for CC views over MLO projection when evaluating lesion conspicuity against BPE (p = 0.045) and no significant preference for the evaluation of lesion visibility (p = 0.078) or confidence in margins (p = 0.35). 

For more information: www.arrs.org 

 


Find more ARRS23 conference coverage here 

 

Related Breast Imaging Content: 


VIDEO: FDA Update on the US National Density Reporting Standard - A Discussion on the Final Rule 


Single vs. Multiple Architectural Distortion on Digital Breast Tomosynthesis 


Today's Mammography Advancements  


Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings  


AI DBT Impact on Mammography Post-breast Therapy  


ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI  


Radiologist Fatigue, Experience Affect Breast Imaging Call Backs  


Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography 


Study Finds Racial Disparities in Access to New Mammography Technology 


American College of Radiology (ACR) Launches Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in Collaboration With GE Healthcare and the Breast Cancer Research Foundation 

 

Related Breast Density Content: 


Creating Patient Equity: A Breast Density Legislative Update 


FDA Needs to Ensure that Information on Dense Breast Notifications are Clear and Understandable to all Members of the Public 


AI Provides Accurate Breast Density Classification 


VIDEO: The Impact of Breast Density Technology and Legislation 


VIDEO: Personalized Breast Screening and Breast Density 


VIDEO: Breast Cancer Awareness - Highlights of the NCoBC 2016 Conference 


Fake News: Having Dense Breast Tissue is No Big Deal 


The Manic World of Social Media and Breast Cancer: Gratitude and Grief


Related Content

News | RSNA

November 22, 2023 — ScreenPoint Medical has announced that its Transpara breast AI has surpassed 5 million mammograms ...

Time November 22, 2023
arrow
News | FDA

November 22, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

Time November 22, 2023
arrow
News | Breast Imaging

November 21, 2023 —iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and CancerIQ ...

Time November 21, 2023
arrow
News | Breast Imaging

November 20, 2023 — The American Society for Radiation Oncology (ASTRO) issued a clinical guideline on partial breast ...

Time November 20, 2023
arrow
News | Digital Radiography (DR)

November 16, 2023 — Boston Imaging, the United States headquarters of Samsung’s digital radiography and ultrasound ...

Time November 16, 2023
arrow
Feature | RSNA | Christine Book

November 8, 2023 — Prepping for another strong meeting, the planners of "RSNA 2023: Leading through Change", presented ...

Time November 08, 2023
arrow
News | Breast Density

November 7, 2023 — Whiterabbit.ai, an AI-technology company dedicated to making late-stage diseases a rarity, announced ...

Time November 07, 2023
arrow
News | Artificial Intelligence

November 6, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is set to ...

Time November 06, 2023
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Imaging advancements, including 3D Doppler imaging to detect cancers in numerous organs, are used to accurately guide ...

Time November 03, 2023
arrow
Feature | Breast Imaging | By Laura Heacock, MS, MD

Breast cancer remains a significant health concern, responsible for more than 600,000 deaths annually. Early detection ...

Time November 03, 2023
arrow
Subscribe Now